RDIF agrees with India on production of 100 mln doses of Sputnik V

MOSCOW, Apr 5 (PRIME) -- The Russian Direct Investment Fund (RDIF) agreed with Indian pharmaceutical company Panacea Biotec on production of 100 million doses of the Sputnik V anti-coronavirus vaccine annually, the fund said in a statement on Monday.

“The RDIF and one of India’s leading vaccines and medicines producer Panacea Biotec announce partnership for annual production of 100 million doses of the world’s first-registered anti-coronavirus vaccine Sputnik V,” it said.

The vaccine will be supplied to the RDIF’s international partners, it added.

End %%as/jst%%